Commentary

Video

A Q-TWiST Analysis from the CheckMate 649 Trial of Nivolumab/Chemo in Advanced Gastric/GEJ Cancer

Author(s):

David B. Zhen, MDSamuel Cytryn, MD

Samuel Cytryn, MD, and David B. Zhen, MD, discuss findings from a Q-TWiST analysis of the CheckMate 649 trial in advanced gastric/GEJ cancer.

Related Videos
Sergio A. Giralt, MD
Rahul Banerjee, MD, FACP
Chih-Yi Liao, MD
Mazyar Shadman, MD, MPH
Anthony B. El-Khoueiry, MD
Craig E. Devoe, MD, MS
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ciara Kelly, MBBCh, BAO
Ryan Hood, BA, MD/MPH student, University of Miami Miller School of Medicine
Related Content
Charles M. Rudin, MD, PhD
September 7th 2024

Ifinatamab Deruxtecan Shows Improved Clinical Activity at Higher Dose in ES-SCLC

Komal Jhaveri, MD, FACP, section head, Endocrine Therapy Research Program, clinical director, Early Drug Development Service, Patricia and James Cayne Chair for Junior Faculty, Memorial Sloan Kettering Cancer Center
August 22nd 2024

Jhaveri on the INAVO120 Trial of Inavolisib/Palbociclib/Fulvestrant in PIK3CA -Mutant, HR+ Breast Cancer

Stefan K. Barta, MD, MS
September 5th 2024

Immunotherapy Could Represent New Treatment Avenue in T-Cell Lymphoma

Oncology Unplugged
August 7th 2024

Park and Grivas Expand on Treatment Updates in Bladder Cancer

Solange Peters, MD, PhD
September 4th 2024

Novel Targets, Classes of Agents Could Refine Checkpoint Inhibition in NSCLC

OncLive’s August Roundup of Key FDA Approvals in Oncology
September 4th 2024

OncLive’s August Roundup of Key FDA Approvals in Oncology